Cargando…

Mitochondrial morphology and MAVS‐IFN1 signaling pathway in muscles of anti‐MDA5 dermatomyositis

OBJECTIVE: This study aimed to investigate mitochondrial changes and the mitochondrial antiviral‐signaling protein (MAVS)‐type I interferon (IFN1) signaling pathway in the muscles of anti‐melanoma differentiation gene 5(MDA5) dermatomyositis (DM) patients. METHODS: Eleven anti‐MDA5 DM and ten antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yanyan, Liu, Yilin, Zhao, Yawen, Zheng, Yiming, Yu, Meng, Deng, Jianwen, Hao, Hongjun, Zhang, Wei, Wang, Zhaoxia, Yuan, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951095/ https://www.ncbi.nlm.nih.gov/pubmed/33576578 http://dx.doi.org/10.1002/acn3.51311

Ejemplares similares

Comparison of cytokine/chemokine profiles between dermatomyositis and anti-synthetase syndrome
por: Wang, Yikang, et al.
Publicado: (2022)

Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis
por: Wang, Yan, et al.
Publicado: (2023)

7. Anti-MDA5 associated dermatomyositis
por: Laverty, Ursula, et al.
Publicado: (2019)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

On the Nose: Anti-MDA-5 Dermatomyositis Manifesting as Perinasal Swelling
por: Molina, Emily, et al.
Publicado: (2022)

Anti-MDA5 Amyopathic Dermatomyositis—A Diagnostic and Therapeutic Challenge
por: Bobirca, Anca, et al.
Publicado: (2022)

Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022)

Subcutaneous Calcinosis in a Patient with Anti-MDA5 Positive Dermatomyositis
por: Hou, Ruihong, et al.
Publicado: (2021)

Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome
por: Zuo, Yu, et al.
Publicado: (2022)

Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis
por: De Luna, Noemí, et al.
Publicado: (2017)

The MAVS and MAV-Nots: PINK1 Clears Prion-like MAVS Aggregates to Extinguish Mitochondrial Inflammatory Signaling
por: Rai, Prashant, et al.
Publicado: (2021)

Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
por: Labrador-Horrillo, Moises, et al.
Publicado: (2014)

Anti-MDA5 antibody-positive dermatomyositis presenting as unilateral eyelid edema
por: Chen, Lauren, et al.
Publicado: (2020)

Anti-MDA-5 Dermatomyositis With Development of Drug-Mediated Necrolytic Skin Lesions
por: Case, Robert A., et al.
Publicado: (2020)

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies
por: Nombel, Anaïs, et al.
Publicado: (2021)

Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis
por: So, Ho, et al.
Publicado: (2022)

Pathogenesis of anti-melanoma differentiation-associated gene-5 (MDA5) dermatomyositis
por: Weng, Chenghua, et al.
Publicado: (2022)

Cardiac involvement in anti-MDA5 dermatomyositis: a case-based review
por: Quintero-González, Diana C., et al.
Publicado: (2022)

Case Report: Anti-MDA-5 dermatomyositis in a resource-limited setting
por: Risal, Ujjwol, et al.
Publicado: (2023)

Machine learning for screening and predicting the risk of anti-MDA5 antibody in juvenile dermatomyositis children
por: Xue, Yuan, et al.
Publicado: (2023)

Flavivirus prM interacts with MDA5 and MAVS to inhibit RLR antiviral signaling
por: Sui, Liyan, et al.
Publicado: (2023)

Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis
por: Kotsiou, Ourania S., et al.
Publicado: (2017)

Therapiealternativen bei amyopathischer MDA5-positiver Dermatomyositis
por: Schumacher, Falk, et al.
Publicado: (2023)

Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis
por: Li, Liubing, et al.
Publicado: (2017)

Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry
por: Mehta, Pankti, et al.
Publicado: (2021)

Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody
por: Kishida, Dai, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis
por: Liu, Tao, et al.
Publicado: (2022)

Duck TRIM29 negatively regulates type I IFN production by targeting MAVS
por: Li, Weiqiang, et al.
Publicado: (2023)

Anti-melanoma Differentiation-Associated Gene 5 (Anti-MDA5) Dermatomyositis: A Case Presentation
por: Ruppel, Tyler, et al.
Publicado: (2022)

Coexistence of anti‐MDA5 and anti‐PL‐7 in a patient with dermatomyositis: A case report
por: Fu, Hongyan, et al.
Publicado: (2023)

Research Note: Interactions among the MDA5, MAVS, and STING signaling pathways in chicken cells
por: Shin, Seung Pyo, et al.
Publicado: (2023)

Hypomyopathic Dermatomyositis Presenting with Idiopathic CD4 T-lymphocytopenia and Delayed Anti-MDA5 Positivity
por: Mijares, Maria C, et al.
Publicado: (2019)

Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review
por: Kersey, Cooper B., et al.
Publicado: (2021)

Cutaneous Features of Anti-MDA-5 Antibody-Positive Amyopathic Dermatomyositis in a Sudanese Patient
por: Alqahtani, Nouf, et al.
Publicado: (2021)

Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review
por: Gonzalez, Daniel, et al.
Publicado: (2022)

82 Juvenile dermatomyositis with early-onset anti-MDA 5 antibodies: a case report
por: Ayad, N, et al.
Publicado: (2022)

Mechanic’s Hand Heralding Relapse in an Indian Adolescent with Anti-MDA5 Positive Juvenile Dermatomyositis
por: Ganatra, Keya, et al.
Publicado: (2022)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Acquired Reactive Perforating Collagenosis – A Rare Cutaneous Manifestation of Anti-MDA5 Dermatomyositis
por: Gan, Teck Sheng, et al.
Publicado: (2022)

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_87se93tjtg685l25vdjia215fo